New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 17, 2012
06:28 EDTHEBHemispherx's fatigue drug to be reviewed again by FDA, WSJ reports
A potential treatment for chronic fatigue syndrome will be reviewed again this week when an FDA panel looks at Hemispherx Biopharma's (HEB) experimental drug Ampligen, reports the Wall Street Journal. The drug has been in development for chronic fatigue syndrome for about two decades, but in 2009 the FDA refused to approve it, saying clinical studies submitted for approval of the product didn't provide "credible evidence" of the drug's effectiveness. Reference Link
News For HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
08:37 EDTHEBHemispherx exploring possible research program in Zika Virus
Subscribe for More Information
February 3, 2016
08:46 EDTHEBHemispherx announces voluntary stock purchase plan
Hemispherx Biopharma announced a Voluntary Pay for Stock Plan. Hemispherx Biopharma is seeking to create ownership incentives as well as to provide additional cash for various operational activities. All members of Senior Management, all members of the board, and all employees volunteered to participate. Senior Management believes that this Plan creates significant shareholder value as the participants will voluntarily use up to 20% of their salaries to purchase stock from the company, creating long term incentives for them to reach corporate goals. In addition, the CEO/Chairman and President/CFO, will both voluntarily reduce their salaries further to a cumulative reduction of 50%. The plan goes into effect immediately.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use